Literature DB >> 24411482

Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology.

Miranda E Orr1, Angelica Salinas1, Rochelle Buffenstein1, Salvatore Oddo2.   

Abstract

High sugar consumption and diabetes increase the risk of developing Alzheimer's disease (AD) by unknown mechanisms. Using an animal model of AD, here we show that high sucrose intake induces obesity with changes in central and peripheral insulin signaling. These pre-diabetic changes are associated with an increase in amyloid-β production and deposition. Moreover, high sucrose ingestion exacerbates tau phosphorylation by increasing Cdk5 activity. Mechanistically, the sucrose-mediated increase in AD-like pathology results from hyperactive mammalian target of rapamycin (mTOR), a key nutrient sensor important in regulating energy homeostasis. Specifically, we show that rapamycin, an mTOR inhibitor, prevents the detrimental effects of sucrose in the brain without altering changes in peripheral insulin resistance. Overall, our data suggest that high sucrose intake and dysregulated insulin signaling, which are known to contribute to the occurrence of diabetes, increase the risk of developing AD by upregulating brain mTOR signaling. Therefore, early interventions to modulate mTOR activity in individuals at high risk of developing diabetes may decrease their AD susceptibility.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APP; Amyloid-β; Diabetes; Insulin resistance; Tangles; Tau

Mesh:

Substances:

Year:  2013        PMID: 24411482      PMCID: PMC3973159          DOI: 10.1016/j.neurobiolaging.2013.12.006

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  61 in total

1.  Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.

Authors:  Konstanze Plaschke; Juergen Kopitz; Markus Siegelin; Reinhard Schliebs; Melita Salkovic-Petrisic; Peter Riederer; Siegfried Hoyer
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.

Authors:  Antonella Caccamo; Smita Majumder; Arlan Richardson; Randy Strong; Salvatore Oddo
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

4.  Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.

Authors:  Hui H Zhang; Jingxiang Huang; Katrin Düvel; Bernard Boback; Shulin Wu; Rachel M Squillace; Chin-Lee Wu; Brendan D Manning
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

5.  Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Authors:  Patricia Spilman; Natalia Podlutskaya; Matthew J Hart; Jayanta Debnath; Olivia Gorostiza; Dale Bredesen; Arlan Richardson; Randy Strong; Veronica Galvan
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

6.  Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

Authors:  Ying Liu; Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

Review 7.  Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation.

Authors:  Jean-François Tanti; Jennifer Jager
Journal:  Curr Opin Pharmacol       Date:  2009-08-13       Impact factor: 5.547

Review 8.  mTOR-dependent signalling in Alzheimer's disease.

Authors:  Jin-Jing Pei; Jacques Hugon
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

9.  Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Yazi D Ke; Fabien Delerue; Amadeus Gladbach; Jürgen Götz; Lars M Ittner
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

10.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Authors:  David E Harrison; Randy Strong; Zelton Dave Sharp; James F Nelson; Clinton M Astle; Kevin Flurkey; Nancy L Nadon; J Erby Wilkinson; Krystyna Frenkel; Christy S Carter; Marco Pahor; Martin A Javors; Elizabeth Fernandez; Richard A Miller
Journal:  Nature       Date:  2009-07-08       Impact factor: 49.962

View more
  34 in total

Review 1.  Mechanisms of oxidative stress resistance in the brain: Lessons learned from hypoxia tolerant extremophilic vertebrates.

Authors:  Valentina R Garbarino; Miranda E Orr; Karl A Rodriguez; Rochelle Buffenstein
Journal:  Arch Biochem Biophys       Date:  2015-04-01       Impact factor: 4.013

2.  Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer's disease.

Authors:  Roger J Mullins; Maja Mustapic; Edward J Goetzl; Dimitrios Kapogiannis
Journal:  Hum Brain Mapp       Date:  2017-01-20       Impact factor: 5.038

3.  Sugary beverage intake and preclinical Alzheimer's disease in the community.

Authors:  Matthew P Pase; Jayandra J Himali; Paul F Jacques; Charles DeCarli; Claudia L Satizabal; Hugo Aparicio; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2017-03-06       Impact factor: 21.566

4.  Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Eric Ferreira; Thuy-Vi Nguyen; Kristian Doyle; Antonella Caccamo; Salvatore Oddo
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

5.  Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.

Authors:  Zhong-Hao Zhang; Qiu-Yan Wu; Rui Zheng; Chen Chen; Yao Chen; Qiong Liu; Peter R Hoffmann; Jia-Zuan Ni; Guo-Li Song
Journal:  J Neurosci       Date:  2017-01-30       Impact factor: 6.167

6.  Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease.

Authors:  Antonella Caccamo; Ramona Belfiore; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2018-04-05       Impact factor: 4.673

7.  Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Elena V Wisely; Lauren K Hartman; Antonella Caccamo; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2014-06-16       Impact factor: 4.673

8.  Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.

Authors:  Antonella Caccamo; Vito De Pinto; Angela Messina; Caterina Branca; Salvatore Oddo
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

Review 9.  Intergenerational Metabolic Syndrome and Neuronal Network Hyperexcitability in Autism.

Authors:  Aileen Rivell; Mark P Mattson
Journal:  Trends Neurosci       Date:  2019-09-05       Impact factor: 13.837

Review 10.  Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease.

Authors:  Veronica Galvan; Matthew J Hart
Journal:  Biochim Biophys Acta       Date:  2015-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.